Comparation of the combined therapies of oral contraceptive-spironolactone and oral contraceptive-cyproterone acetate on Hirsutizm treatment

Basit Öğe Kaydı
dc.authorscopusid11940231300
dc.authorscopusid7003740112
dc.authorscopusid7004415692
dc.authorscopusid6602675218
dc.contributor.authorYilmaz Aydin G.
dc.contributor.authorYüce M.A.
dc.contributor.authorGücer F.
dc.contributor.authorBalkânli-Kaplan P.
dc.date.accessioned2024-06-12T10:28:13Z
dc.date.available2024-06-12T10:28:13Z
dc.date.issued2005
dc.description.abstractOBJECTIVE: To compare clinical effectiveness and effects on hormonal levels of the combined drug therapies of oral contraceptives plus spironolactone or cyproterone acetate on patients have complaints with hirsutism. STUDY DESIGN: 96 Hirsute women referred to Trakya University Medical Faculty, Department of Obstetrics&Gynecology were included into this study. Of the 69 patients, 34 of them (Group 1) treated with combined oral contraceptive including Cyproterone acetate 2 mg ve etinyl estradiol 35 ?g and spironolactone 100 mg/gün, 35 of them treated with the same contraseptive combined with high dose cyproterone acetate (50 mg/gün). Clinical hirsutism shores and serum androgen levels were evaluated at the begining, sixth months and the end of the first year. RESULTS: We showed that both of the treatment modalities decreased hirsutizm scores and improved clinical complaints in the same effectiveness. At the end of the treatment, serum free testesterone and DHEAS levels decreased, SHBG levels increased significantly in the both treatment groups. While serum total testesterone levels decreased only in OC plus spironolactone treated group significantly, there were no significant difference in androstenedione levels after the both combined therapies. CONCLUSION: Both of the drug combinations were the same clinic and anti-androgenic effectiveness, So that, we could prefer one of the therapies in light of the side effect spectrum.en_US
dc.identifier.endpage221en_US
dc.identifier.issn1016-5126
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-31344460799en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage215en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17141
dc.identifier.volume19en_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.relation.ispartofJinekoloji ve Obstetrik Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAndrogens; Hirsutism; Oc; Sypronolactone; Syproterone Acetateen_US
dc.subjectAndrogen; Androstenedione; Cyproterone Acetate; Diane; Ethinylestradiol; Oral Contraceptive Agent; Prasterone Sulfate; Sex Hormone Binding Globulin; Spironolactone; Testosterone; Adolescent; Adult; Androgen Blood Level; Article; Clinical Trial; Combination Chemotherapy; Drug Effect; Drug Efficacy; Drug Megadose; Female; Hirsutism; Human; Major Clinical Study; Testosterone Blood Level; Turkey (Republic)en_US
dc.titleComparation of the combined therapies of oral contraceptive-spironolactone and oral contraceptive-cyproterone acetate on Hirsutizm treatmenten_US
dc.title.alternativeHirsutizm tedavisinde oral kontraseptif-spironolakton ve oral kontraseptif-siproteron asetat kombinasyonlarinin karşilaş tirilmasien_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu